 | • レポートコード：MRC2303F0230 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、246ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥732,452 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,472,452 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査資料は、2021年に552.51百万ドルであった世界の非オピオイド疼痛パッチ市場規模が、2022年に622.13百万ドルになり、2027年まで年平均12.77%で成長して1,136.75百万ドルに到達すると予想しています。本調査資料では、非オピオイド疼痛パッチの世界市場について調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、パッチ種類別（カプサイシンパッチ、ジクロフェナクパッチ、ケトプロフェンパッチ、リドカインパッチ、サリチル酸メチルパッチ）分析、疾患別（関節炎、背中痛、線維筋痛症、偏頭痛＆頭痛、筋緊張＆捻挫）分析、流通別（ドラッグストア、病院、オンライン薬局）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などを以下の構成でまとめております。さらに、市場参入企業として、3M Company、Abbott Laboratories、AstraZeneca PLC、B. Braun Melsungen AG、Baxter International Inc.、Cardinal Health, Inc.、Eli Lilly and Company、Endo International PLC、Hisamitsu Pharmaceutical Co., Inc.、Johnson & Johnson、Medtronic PLC、Merck KGaA、Novartis AG、PerkinElmer, Inc.、Pfizer Inc.、Sorrento Therapeutics, Inc.、TEH SENG Pharmaceutical Mfg. Co., Ltd.などの情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の非オピオイド疼痛パッチ市場規模：パッチ種類別 - カプサイシンパッチの市場規模 - ジクロフェナクパッチの市場規模 - ケトプロフェンパッチの市場規模 - リドカインパッチの市場規模 - サリチル酸メチルパッチの市場規模 ・世界の非オピオイド疼痛パッチ市場規模：疾患別 - 関節炎における市場規模 - 背中痛における市場規模 - 線維筋痛症における市場規模 - 偏頭痛＆頭痛における市場規模 - 筋緊張＆捻挫偏頭痛＆頭痛における市場規模 ・世界の非オピオイド疼痛パッチ市場規模：流通別 - ドラッグストアチャネルの市場規模 - 病院チャネルの市場規模 - オンライン薬局チャネルの市場規模 ・世界の非オピオイド疼痛パッチ市場規模：地域別 - 南北アメリカの非オピオイド疼痛パッチ市場規模 アメリカの非オピオイド疼痛パッチ市場規模 カナダの非オピオイド疼痛パッチ市場規模 ブラジルの非オピオイド疼痛パッチ市場規模 ... - アジア太平洋の非オピオイド疼痛パッチ市場規模 日本の非オピオイド疼痛パッチ市場規模 中国の非オピオイド疼痛パッチ市場規模 インドの非オピオイド疼痛パッチ市場規模 韓国の非オピオイド疼痛パッチ市場規模 台湾の非オピオイド疼痛パッチ市場規模 ... -ヨーロッパ/中東/アフリカの非オピオイド疼痛パッチ市場規模 イギリスの非オピオイド疼痛パッチ市場規模 ドイツの非オピオイド疼痛パッチ市場規模 フランスの非オピオイド疼痛パッチ市場規模 ロシアの非オピオイド疼痛パッチ市場規模 ... -その他地域の非オピオイド疼痛パッチ市場規模 ・競争状況 ・企業情報 |
The Global Non-opioid Pain Patches Market size was estimated at USD 552.51 million in 2021 and expected to reach USD 622.13 million in 2022, and is projected to grow at a CAGR 12.77% to reach USD 1,136.75 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Non-opioid Pain Patches to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Patch Type, the market was studied across Capsaicin Patches, Diclofenac Patches, Ketoprofen Patches, Lidocaine Patches, and Methyl Salicylate Patches.
Based on Indication, the market was studied across Arthritis, Back Pain, Fibromyalgia, Migraines & Headaches, Muscle Strain & Sprains, and Post-herpetic Neuralgia.
Based on Distribution, the market was studied across Drug Stores, Hospitals, and Online Pharmacies.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Non-opioid Pain Patches market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Non-opioid Pain Patches Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Non-opioid Pain Patches Market, including 3M Company, Abbott Laboratories, AstraZeneca PLC, B. Braun Melsungen AG, Baxter International Inc., Cardinal Health, Inc., Eli Lilly and Company, Endo International PLC, Hisamitsu Pharmaceutical Co., Inc., Johnson & Johnson, Medtronic PLC, Merck KGaA, Novartis AG, PerkinElmer, Inc., Pfizer Inc., Sorrento Therapeutics, Inc., TEH SENG Pharmaceutical Mfg. Co., Ltd., Teikoku Seiyaku Co., Ltd., Thermo Fisher Scientific Inc., Viatris Inc., and Virpax Pharmaceuticals, Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Non-opioid Pain Patches Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Non-opioid Pain Patches Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Non-opioid Pain Patches Market?
4. What is the competitive strategic window for opportunities in the Global Non-opioid Pain Patches Market?
5. What are the technology trends and regulatory frameworks in the Global Non-opioid Pain Patches Market?
6. What is the market share of the leading vendors in the Global Non-opioid Pain Patches Market?
7. What modes and strategic moves are considered suitable for entering the Global Non-opioid Pain Patches Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing Chronic and Acute Pain-Related Disorders
5.1.1.2. Growing Inclination of Healthcare Professionals towards Non-Opioid Patches
5.1.1.3. Benefits Associated with Non-opioid Pain Patches over Conventional Medications
5.1.2. Restraints
5.1.2.1. Limited Awareness Associated with Non-opioid Pain Patches
5.1.3. Opportunities
5.1.3.1. Favorable Government Initiatives towards Non-Addictive Pain Therapeutic Solutions
5.1.3.2. Rising R&D in Pain Management Treatments
5.1.4. Challenges
5.1.4.1. Significant Side Effect Coupled with Availability of Alternative Treatments
5.2. Cumulative Impact of COVID-19
6. Non-opioid Pain Patches Market, by Patch Type
6.1. Introduction
6.2. Capsaicin Patches
6.3. Diclofenac Patches
6.4. Ketoprofen Patches
6.5. Lidocaine Patches
6.6. Methyl Salicylate Patches
7. Non-opioid Pain Patches Market, by Indication
7.1. Introduction
7.2. Arthritis
7.3. Back Pain
7.4. Fibromyalgia
7.5. Migraines & Headaches
7.6. Muscle Strain & Sprains
7.7. Post-herpetic Neuralgia
8. Non-opioid Pain Patches Market, by Distribution
8.1. Introduction
8.2. Drug Stores
8.3. Hospitals
8.4. Online Pharmacies
9. Americas Non-opioid Pain Patches Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Non-opioid Pain Patches Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Non-opioid Pain Patches Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. 3M Company
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Abbott Laboratories
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. AstraZeneca PLC
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. B. Braun Melsungen AG
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Baxter International Inc.
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Cardinal Health, Inc.
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Eli Lilly and Company
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Endo International PLC
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Hisamitsu Pharmaceutical Co., Inc.
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Johnson & Johnson
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Medtronic PLC
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Merck KGaA
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Novartis AG
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. PerkinElmer, Inc.
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Pfizer Inc.
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Sorrento Therapeutics, Inc.
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. TEH SENG Pharmaceutical Mfg. Co., Ltd.
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Teikoku Seiyaku Co., Ltd.
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Thermo Fisher Scientific Inc.
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Viatris Inc.
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. Virpax Pharmaceuticals, Inc.
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing